Healthcare

Clinuvel Pharmaceuticals Limited (ASX:CUV) operates through its own product and service model. SCENESSE contains afamelanotide and is administered as a subcutaneous implant by trained clinical personnel. In August 2026 Clinuvel separately updated its work on an injectable peptide platform, describing preclinical development activity.

Cambium Bio Limited (ASX:CMB) operates through its own product and service model. Proposed secretome-derived approaches are intended to investigate the effects of cell-secreted substances on ocular tissues. References to stem-cell exosomes should not imply that a treatment has already demonstrated clinical efficacy or received …

Conventional CRT coordinates heart contractions by applying electrical stimulation through implanted leads. Those leads can present placement challenges or complications for some patients. EBR Systems (ASX:EBR) uses an alternative configuration: an implanted transmitter sends ultrasound energy to a small electrode positioned inside the left …

EMVision Medical Devices Limited (ASX:EMV) develops portable, non-invasive neurodiagnostic technology intended to bring brain assessment closer to patients. Its work centres on the emu bedside scanner and a separate First Responder concept for use before hospital arrival. During 2026, EMVision continued clinical evaluation and …

On 7 October 2026, Entropy Neurodynamics (ASX:ENP) reported that the first participant in Cohort 2 of its Phase 2 BED study had completed a 60-minute TRP-8803 infusion. The participant received treatment on 5 October and was discharged after the required post-treatment clinical assessments. The …

Manufacturing is a distinct element of Epsilon Healthcare (ASX:EPN), rather than simply a support function for clinical services. Pharmaceutical production involves controlled processes, testing, documentation and consistent batch handling. These requirements influence the ability to meet customer specifications and deliver products to agreed schedules.

China’s National Medical Products Administration approved the HiRise weight-bearing CT system in October 2026. CurveBeam AI Limited (ASX:CVB) announced the approval on 13 October, following a trading halt requested for the regulatory update. This represents an important distinction between obtaining permission to market a …